Management of Parkinson’s disease

References

• Li SC, Schoenberg BS, Wang CC. A prevalence survey of Parkinson's disease and other movement disorders in the People's Republic of China. Arch. Neural. 42, 655–657 (1985).
   Google Scholar
• Bharucha NE, Bharucha EP, Bharucha AE. Prevalence of parkinson's disease in the Parsi community of Bombay, India. Atli. Neural 45,1321–1323 (1988).
   Google Scholar
• Nurmi E. et al Progression in Parkinson's disease: a positron emission tomography study with a dopamine transporter ligand [18F1CFT. Ann. Neural 47(6), 804–808 (2000).
   Google Scholar
• Lee CS et al 117 viva positron emission tomographic evidence for compensatory changes in presynaptic dopaminergic nerve terminals in Parkinson's disease. Ann. Neural. 47(4), 493–503 (2000).
   Google Scholar
• Brucke T et al SPECT and PET imaging of the dopaminergic system in Parkinson's disease. J. Neural. 247\(Suppl. 4), 2–7 (2000) .
   Google Scholar
• Bao SY et al Imaging of dopamine transporters with technetium-99m TRODAT-1 and single photon emission computed tomography. I Neuroimag. 10(4), 200–203 (2000).
   Google Scholar
• Mozley PD et al Binding of [99mTc1TRODAT-1 to dopamine transporters in patients with Parkinson's disease and in healthy volunteers. J. Nucl. Med. 41(4), 584–589 (2000).
   Google Scholar
• Eising EG et al SPECT imaging with [123I1-beta-CIT in Parkinsonism: comparison of SPECT images obtained by a single-headed and a three-headed gamma camera. Nucl. Med. Commun. 22(2), 145–150 (2001).
   Google Scholar
• Emami-Avedon SS, Ichise M, Lang AE. The use of SPECT in the diagnosis of Parkinson's disease. Can. Assoc. Radiologists J51(3), 189–196 (2000).
   Google Scholar
• Benamer HT et al Correlation of Parkinson's disease severity and duration with 123I-FP-CIT SPECT striatal uptake. May Disonl 15(4), 692–698 (2000).
   Google Scholar
• Tandberg E, Larsen JP, Karlsen K. A community-based study of sleep disorders in patients with Parkinson's disease. May Disond 13(6), 895–899 (1998).
   PubMed Web of Science ®Google Scholar
• •This is a good summary of the sleep disorders associated with PD.
   Google Scholar
• Wetter TC et al Sleep and periodic leg movement patterns in drug-free patients with Parkinson's disease and multiple system atrophy. Sleep 23(3), 361–367 (2000).
   PubMed Web of Science ®Google Scholar
• Cornelia CL et al. Sleep-related violence, injury and REM sleep behavior disorder in Parkinson's disease. Neurology51 (2), 526–529 (1998).
   PubMedGoogle Scholar
• Scott L. Parkinson's disease and dementia with Lewy bodies. Dderly Catell (4), 37–39 (1999).
   Google Scholar
• Aarsland D et al Risk of dementia in Parkinson's disease: a community-based, prospective study. Neurology56(6), 730–736 (2001).
   PubMed Web of Science ®Google Scholar
• •This article is a thorough attempt to define the prevalence of dementia due to PD.
   Google Scholar
• Ah1skog JE, Muenter MD. Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature. Mov. Disord. 16(3), 448–458 (2001).
   Google Scholar
• Rascol O et al A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. 056 Study Group. N. Eng/. Med 342(20), 1484–1491 (2000).
   Google Scholar
• •This article is the basis for initial treatment with dopamine agonists.
   Google Scholar
• Jenner P Factors influencing the onset and persistence of dyskinesia in MPTP-treated primates. Ann. Neural 47(4 Suppl. 1), S90-99; discussion S99-104 (2000).
   Google Scholar
• Jenner P. Pathophysiology and biochemistry of dyskinesia: clues for the development of non-dopaminergic treatments. j Neural. 247\(Suppl. 2), 43–50 (2000).
   Google Scholar
• Fornai F et al Dose-dependent protective effects of apomorphine against methamphetamine-induced nigrostriatal damage. Brain Res. 898(1), 27–35 (2001).
   Google Scholar
• Iida M et al Dopamine D2 receptor- mediated anti-oxidant and neuroprotective effects of ropinirole, a dopamine agonist. Brain Res. 838(1–2), 51–59 (1999).
   Google Scholar
• Sawada H et al Dopamine D2-type agonists protect mesencephalic neurons from glutamate neurotoxicity: mechanisms of neuroprotective treatment against oxidative stress. Ann. Neural 44(1), 110–119 (1998).
   Google Scholar
• Zou L et al Neuroprotection by pramipexole against dopamine- and levodopa-induced cytotoxicity. Life ScL 64(15), 1275–1285 (1999).
   Google Scholar
• Parkinson's Study Group, Effect of deprenyl on the progression of disability in early Parkinson's disease. N Engl. j Med. 321, 1364–1371 (1989).
   Google Scholar
• Parkinson's Study Group, Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease. N Engl. Med 328,176-183 (1993).
   Google Scholar
• Waters C. Catechol-O-methyltransferase (COMT) inhibitors in Parkinson's disease. Am. Geriat. Soc. 48(6), 692–698 (2000).
   Google Scholar
• Brooks DJ et al The role of entacapone in the management of Parkinson's disease. Hasp. Med. (London) 61(4), 267–271 (2000). 873–878 (2000).
   Google Scholar
• Giladi N et al. Freezing of gait in patients with advanced Parkinson's disease. j Neural Bansmission (Budapest) 108(1), 53–61 (2001).
   PubMed Web of Science ®Google Scholar
• Luginger E et al Beneficial effects of amantadine on L-dopa-induced dyskinesias in Parkinson’s disease. Mov. Disord. 15(5), 873–878 (2000).
   Google Scholar
• Burchiel KJ et al Comparison of pallidal and subthalamic nucleus deep brain stimulation for advanced Parkinson's disease: results of a randomized, blinded pilot study. Neurosurg 45(6), 1375–1384 (1999).
   PubMed Web of Science ®Google Scholar
• Baron MS et al Treatment of advanced Parkinson's disease by unilateral posterior GPi pallidotomy: 4-year results of a pilot study. May Disond 15(2), 230–237 (2000).
   Google Scholar
• Jost WH. Costs in the treatment of parkinsonism. j Neural. 247\(Suppl. 4), IV/ 31–33 (2000).
   Google Scholar
• Lang AE. Surgery for levodopa-induced dyskinesias. Ann. Neural. 47(4 Suppl. 1), S193-202 (2000).
   Google Scholar
• Kumar R etal. Deep brain stimulation of the globus pallidus pars interna in advanced Parkinson's disease. Neurology55(12 Suppl. 6), S34-39 (2000).
   Google Scholar
• Kumar R etal. Double-blind evaluation of subthalamic nucleus deep brain stimulation in advanced Parkinson's disease. Neurology 51(3), 850–855 (1998).
   PubMedGoogle Scholar
• Krauss JK et al Concepts and methods in chronic thalamic stimulation for treatment of tremor: technique and application. Neurosurgery 48 (3), 535–541; discussion 541–543 (2001).
   Google Scholar
• Limousin P et al. Electrical stimulation of the subthalamic nucleus in advanced Parkinson's disease. N Engl j Med. 339(16), 1105–1111 (1998).
   Google Scholar
• Tomaszewski KJ, Holloway RG. Deep brain stimulation in the treatment of Parkinson's disease: A cost-effectiveness analysis. Neurology57(4), 663–670 (2001).
   PubMed Web of Science ®Google Scholar
• Freed CR, Greene PE, Breeze RE. Transplantation of embryonic dopamine neurons for severe Parkinson's disease. N Engl Med 344,710–719 (2001).
   Google Scholar
• Hauser RA et al Long-term evaluation of bilateral fetal nigral transplantation in Parkinson's disease. Arch. Neural. 56(2), 179–187 (1999).
   PubMed Web of Science ®Google Scholar
• Greene PE, Fahn S, Tsai WY. Severe spontaneous dyskinesias: A disabling complication of embryonic dopaminergic tissue implants in a subset of transplanted patients with advanced Parkinson's disease. May Disord 14,904 (1999).
   Google Scholar
• Jankovic J. Complications and limitations of drug therapy for Parkinson's disease. Neurology55 (12 Suppl. 6), S2-6 (2000).
   Google Scholar
• ••This article is a good summary of thecomplications of drug therapy for PD.
   Google Scholar
• Juncos JL. Management of psychotic aspects of Parkinson's disease. J. Clin. Psychiatry 60\(Suppl. 8), 42–53 (1999).
   Google Scholar
• •This is a good synopsis of the approach to drug induced psychosis.
   Google Scholar
• Factor SA et al Clozapine for the treatment of drug-induced psychosis in Parkinson's disease: results of the 12 week open label extension in the PSYCLOPS trial. May Disord 16(1), 135–139 (2001).
   Google Scholar
• Fernandez HH et al Quetiapine for the treatment of drug-induced psychosis in Parkinson's disease. May Disord 14(3), 484–487 (1999).
   PubMed Web of Science ®Google Scholar
• Baatile J et al Effect of exercise on perceived quality of life of individuals with Parkinson's disease. J. Rehabil Res. Develop. 37(5), 529–534 (2000).
   Google Scholar
• Aarsland D, Cummings JL, Larsen JR Neuropsychiatric differences between Parkinson's disease with dementia and Alzheimer's disease. Int. J. Geriatric Psychiatry16(2), 184–191 (2001).
   Google Scholar
• Hurtig HI et al Alpha-synuclein cortical Lewy bodies correlate with dementia in Parkinson's disease. Neurology 54 (10), 1916–1921 (2000).
   PubMed Web of Science ®Google Scholar
• Rojas-Fernandez CH. Successful use of donepezil for the treatment of dementia with Lewy bodies. Ann. Pharmacothec 35(2), 202–205 (2001).
   PubMedGoogle Scholar
• Montgomery EB, Jr. et al Early detection of probable idiopathic Parkinson's disease: I. Development of a diagnostic test battery. May Disord 15(3), 467–473 (2000).
   Google Scholar
• Montgomery EB, Jr., Lyons K, Koller WC. Early detection of probable idiopathic Parkinson's disease: II. A prospective application of a diagnostic test battery. May Disord 15(3), 474–478 (2000).
   PubMedGoogle Scholar
• Stoof JC et al Leads for the development of neuroprotective treatment in Parkinson's disease and brain imaging methods for estimating treatment efficacy. Eric J. Pharmacol 375(1-3), 75–86 (1999).
   Google Scholar
• Brooks DJ. The early diagnosis of Parkinson's disease. Ann. Neural. 44(3 Suppl. 1), S10-18 (1998).
   Google Scholar
• Gash DM, Zhang Z, Gerhardt G. Neuroprotective and neurorestorative properties of GDNF. Ann. Neural. 44(3 Suppl. 1), S121-125 (1998).
   Google Scholar
• Grondin R, Gash DM. Glial cell line- derived neurotrophic factor (GDNF): a drug candidate for the treatment of Parkinson's disease. J. Neural. 245(11 Suppl. 3), 35–42 (1998).
   Google Scholar
• Collier TJ, Sortwell CE. Therapeutic potential of nerve growth factors in Parkinson's disease. Drugs Aging 14(4). 261–287 (1999).
   PubMedGoogle Scholar
• Lucking CB et al Association between early-onset Parkinson's disease and mutations in the parkin gene. French Parkinson's disease Genetics Study Group. N. Engl Med 342(21), 1560–1567 (2000).
   Google Scholar
• Stefanis L et al Synudein-1 is selectively upregulated in response to nerve growth factor treatment in PC12 cells. J. Neurochem. 76(4), 1165–1176 (2001).
   Google Scholar
• Gu WJ et al. Cloning of rat parkin cDNA and distribution of parkin in rat brain. J. Neurochem. 74(4), 1773–1776 (2000).
   PubMedGoogle Scholar
• Choi P etal. Parkin is metabolized by the ubiquitin/proteosome system. Neuroreport 11(12), 2635–2638 (2000).
   PubMedGoogle Scholar
• Ishida A, Yasuzumi E Approach to ex vivo gene therapy in the treatment of Parkinson's disease. Brain Develop. 22 (Suppl. 1), S143-147 (2000).
   Google Scholar
• Freese A. Restorative gene therapy approaches to Parkinson's disease. Med Clin. North 4m. 83(2), 537–548 (1999).
   Google Scholar
• Latchman DS, Coffin RS. Viral vectors for gene therapy in Parkinson's disease. Rev Neurosci 12(1), 69–78 (2001).
   PubMedGoogle Scholar
• Ozawa K et al Gene therapy of Parkinson's disease using adeno-associated virus (AAV) vectors. J. Neural Transmission 58 (Suppl.), 181–191 (2000).
   Google Scholar
• Ridet L, Deglon N, Aebischer P Gene transfer techniques for the delivery of GDNF in Parkinson's disease. Novartis Foundation Symposium, 231,202–219 (2000).
   PubMedGoogle Scholar
• Dunnett SB, Bjorklund A. Prospects for new restorative and neuroprotective treatments in Parkinson's disease. Nature 399(6738 Suppl.), A32-39 (1999).
   Google Scholar
• Chen JF et al. Neuroprotection by caffeine and A(2A) adenosine receptor inactivation in a model of Parkinson's disease. J. Neurosci 21(10), RC143 (2001).
   Google Scholar
• Costantini LC etal. Immunophilin ligands can prevent progressive dopaminergic degeneration in animal models of Parkinson's disease. Eur j Neurosci 13(6), 1085–1092 (2001).
   PubMedGoogle Scholar
• Suuronen TP, Kolehmainen, Salminen A. Protective effect of L-deprenyl against apoptosis induced by okadaic acid in cultured neuronal cells. Biochem. Phatmacol. 59(12), 1589–1595 (2000).
   Google Scholar
• Koller WC. Neuroprotection for Parkinson's disease. Ann. Neural 44(3 Suppl. 1), S155-159 (1998).
   Google Scholar
• •This is a good review of attempts to define netupprotection in PD.
   Google Scholar
• Olanow CW, Watts RL, Koller WC. An algorithm (decision tree) for the management of Parkinson's disease (2001): treatment guidelines. Neumlogy56(11 Suppl. 5), S1—S88 (2001).
   Google Scholar